1. Home
  2. CCB vs XERS Comparison

CCB vs XERS Comparison

Compare CCB & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coastal Financial Corporation

CCB

Coastal Financial Corporation

HOLD

Current Price

$82.29

Market Cap

1.3B

Sector

Finance

ML Signal

HOLD

XERS

Xeris Biopharma Holdings Inc.

HOLD

Current Price

$6.07

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CCB
XERS
Founded
1997
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.3B
1.1B
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
CCB
XERS
Price
$82.29
$6.07
Analyst Decision
Strong Buy
Buy
Analyst Count
3
6
Target Price
$126.67
$10.83
AVG Volume (30 Days)
113.2K
1.5M
Earning Date
04-27-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
100.00
EPS
3.06
N/A
Revenue
N/A
$49,590,000.00
Revenue This Year
$96.61
$34.37
Revenue Next Year
$22.66
$22.86
P/E Ratio
$27.31
N/A
Revenue Growth
N/A
142.67
52 Week Low
$70.72
$4.26
52 Week High
$120.05
$10.08

Technical Indicators

Market Signals
Indicator
CCB
XERS
Relative Strength Index (RSI) 54.38 51.75
Support Level $73.44 $5.76
Resistance Level $85.88 $6.41
Average True Range (ATR) 2.21 0.24
MACD 0.32 0.02
Stochastic Oscillator 58.03 46.57

Price Performance

Historical Comparison
CCB
XERS

About CCB Coastal Financial Corporation

Coastal Financial Corp is a bank holding company. Through its subsidiaries, the company conducts its business in three reportable segments which include, Community Bank, CCBX, and Treasury and Administration. The Community Bank segment includes all community banking activities, with a primary focus on providing various banking products and services to consumers and small to medium-sized businesses. The CCBX segment provides Banking as a Service (BaaS) that allows its broker dealers and digital financial service partners to offer their customers banking services, and the Treasury and administration segment includes treasury management, overall administration, and all other aspects of the company. The maximum revenue of the company is generated from the CCBX segment.

About XERS Xeris Biopharma Holdings Inc.

Xeris Biopharma Holdings Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offers Recorlev for the treatment of endogenous hypercortisolemia in patients with Cushing's syndrome; Gvoke for the treatment of severe hypoglycemia; and Keveyis for the treatment of Primary Periodic Paralysis (PPP). Additionally, the company is advancing its Phase 3-ready pipeline product, XP-8121, a once-weekly subcutaneous injection of levothyroxine, which leverages its proprietary technology, XeriSol.

Share on Social Networks: